Skip to content
Screener

Fulgent Genetics, Inc. FLGT Noncontrolling interests in subsidiaries

Noncontrolling interests in subsidiaries at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
$303M+719%

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$526.64M-16.5%
Enterprise value$511.45M-6.7%
P/S1.6×-0.4×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 7:08 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-199065
Line itemMarch 31, 2026December 31, 2025
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding as of March 31, 2026, and December 31, 2025
Additional paid-in capital540,141574,520
Accumulated other comprehensive income4,5367,512
Retained earnings505,128529,954
Total Fulgent stockholders’ equity1,049,8091,111,989
Noncontrolling interest(5,655)(5,274)
Total stockholders’ equity1,044,1541,106,715
Total liabilities and stockholders’ equity$1,156,369$1,213,525

Item 1. Financial Statements.

FAQ

What is Fulgent Genetics, Inc.'s noncontrolling interests in subsidiaries?
Fulgent Genetics, Inc. (FLGT) reported noncontrolling interests in subsidiaries of -$5.66M in Q1 2026.
How has Fulgent Genetics, Inc.'s noncontrolling interests in subsidiaries changed year-over-year?
Fulgent Genetics, Inc.'s noncontrolling interests in subsidiaries decreased by 28.3% year-over-year, from -$4.41M to -$5.66M.
What is the long-term trend for Fulgent Genetics, Inc.'s noncontrolling interests in subsidiaries?
Over 4 years (2021 to 2025), Fulgent Genetics, Inc.'s noncontrolling interests in subsidiaries has grown at a -7.3% compound annual growth rate (CAGR), from $7.13M to -$5.27M.
What does noncontrolling interests in subsidiaries mean?
This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.

Ask your AI about Fulgent Genetics, Inc.'s noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude